mit media lab digital currency initiative, Reviews

Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.Microsoft: The latest small language model PHI-4, which is specially used for complex reasoning, is introduced.Geely applied for the unbounded intelligent cabin and the unbounded intelligent cabin. According to the information of intellectual property rights, Zhejiang Geely Holding Group Co., Ltd. recently applied for the registration of the trademarks of "Geely Unbounded Intelligent Cabin" and "Geely Unbounded Intelligent Cabin", which are internationally classified as scientific instruments and means of transport. The current trademark status is awaiting substantive examination.

The Shenzhen Stock Exchange terminated the audit of four bond projects with a total amount of 5.879 billion yuan. On December 13, the Shenzhen Stock Exchange recently terminated the audit of four bond projects with a total amount of 5.879 billion yuan, and the varieties were small public offerings and private placements.The 30-year Treasury ETF rose sharply at the opening, hitting a record high. Both "Boshi SSE 30-year Treasury ETF" and "Pengyang China Bond -30-year Treasury ETF" rose by 0.65%.The Hang Seng Index of Hong Kong stocks opened lower by 0.78%, the index of state-owned enterprises fell by 0.88%, and the branch index opened lower by 1.01%.

Zongheng Communication established a new science and technology company in Zhejiang. The enterprise search APP shows that recently, Zongheng Cross-border Technology (Zhejiang) Co., Ltd. was established with Xu Shasha as its legal representative and a registered capital of 10 million yuan. Its business scope includes: sales of information security equipment; Network equipment sales; Internet of things technical services, etc. Enterprise equity penetration shows that the company is wholly owned by Zongheng Communication.Microsoft: The latest small language model PHI-4, which is specially used for complex reasoning, is introduced.Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.